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A new serotonin 5-HT6 receptor 
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binding
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Tania de la Fuente1,‡, Henar Vázquez-Villa1, Javier García-Cárceles1, Joaquín Botta3, 
Peter J. McCormick3, Bellinda Benhamú1, Leonardo Pardo2 & María L. López-Rodríguez1
Serotonin 5-HT6 receptor has been proposed as a promising therapeutic target for cognition 
enhancement though the development of new antagonists is still needed to validate these molecules 
as a drug class for the treatment of Alzheimer’s disease and other pathologies associated with memory 
deficiency. As part of our efforts to target the 5-HT6 receptor, new benzimidazole-based compounds 
have been designed and synthesized. Site-directed mutagenesis and homology models show the 
importance of a halogen bond interaction between a chlorine atom of the new class of 5-HT6 receptor 
antagonists identified herein and a backbone carbonyl group in transmembrane domain 4. In vitro 
pharmacological characterization of 5-HT6 receptor antagonist 7 indicates high affinity and selectivity 
over a panel of receptors including 5-HT2B subtype and hERG channel, which suggests no major cardiac 
issues. Compound 7 exhibited in vivo procognitive activity (1 mg/kg, ip) in the novel object recognition 
task as a model of memory deficit.
The serotonin 5-HT6 receptor (5-HT6R) belongs to the important G-protein coupled receptor (GPCR) superfam-
ily of drug targets1. Extensive investigation has shown that 5-HT6Rs regulate several neurotransmitter pathways 
including at least serotonergic, cholinergic, glutamatergic, and GABAergic systems2. Interestingly, today there is 
compelling evidence that the receptor is involved in learning and memory processes and the ability of 5-HT6R 
antagonists to improve cognitive function has been well established at the preclinical level3,4. Several of them 
have been consistently shown to significantly enhance the memory retention or formation in rodents in multiple 
behavioural models reflecting diverse cognitive tasks. In addition, these antagonists have been demonstrated to 
reverse pharmacologically induced cognitive deficits in a number of cognition paradigms. Further substantiation 
has been provided from emerging clinical data. Indeed, several 5-HT6R antagonists have advanced to clinical 
development, and to date, at least three of them have reached phase II/III trials as drug candidates for cogni-
tive enhancement, which holds promise for these compounds as novel therapeutic agents for the treatment of 
Alzheimer’s disease (AD)5. This neurodegenerative disease is one of the greatest human health challenges in this 
century because of its clinical and socioeconomic impact worldwide. Despite currently available medicines, there 
is still a clear need to develop novel therapeutic approaches with improved overall clinical benefit to alleviate the 
cognitive symptoms of the disease. Therefore, serotonin 5-HT6R has become an attractive drug target for cog-
nition enhancement in AD and other diseases where memory loss and learning complications are symptoms5–7. 
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Nevertheless, the development of new 5-HT6R antagonists is still needed to validate these molecules as a drug 
class for the treatment of AD.
Structure-activity relationship studies as well as complementary methodologies of drug design, such as 
pharmacophore-based and structure-based homology models, have allowed the identification of four common 
key structural elements in 5-HT6R antagonists (Fig. 1A): a positive ionisable atom (PI, in red), an aromatic ring 
(AR, in yellow), a hydrogen bond acceptor group (HBA, in green), and a hydrophobic site (HYD, in blue)8. The 
AR region is occupied by a mono- or bisaryl π -electron donor aromatic or heteroaromatic system (indole ring 
in most cases) that is used as central core, where the remaining pharmacophore features are accommodated in 
an appropriate spatial orientation5. As part of our efforts to develop 5-HT6R antagonists, we have previously 
contributed with a new family of compounds based on a benzimidazole ring as central AR core. Representative 
ligand 1 (Ki = 34 nM) contains 4-methylpiperazine moiety as PI pharmacophore element, a carbonyl group as 
HBA, and a naphthalene ring as HYD (Fig. 1B)9. In the present work we further explore the benzimidazole system 
as a central scaffold to identify 5-HT6R antagonists. In the new series the key structural elements are anchored 
to the benzimidazole ring as depicted in Fig. 1C. Although structural information of the 5-HT6R is presently 
unavailable, the recently provided crystallographic data for the serotonin 5-HT1B and 5-HT2B receptors10,11 and 
mutagenesis studies have been used to develop molecular models of the 5-HT6R in complex with the synthesized 
compounds, which have shown the importance of a halogen bond interaction in the HYD element to stabilize the 
binding. Analogue 7 (Ki = 9 nM) containing (dimethylamino)ethyl fragment as PI, a sulfonamide group as HBA, 
and 5-chloro-2-naphthyl as HYD (Fig. 1D) has been characterized as a selective 5-HT6R antagonist that exhibits 
no important pharmacokinetic issues and in vivo procognitive activity in the novel object recognition task.
Results
In the new compounds (Fig. 1C), a benzene ring was initially maintained as HYD site, while a number of basic 
moieties were considered as PI element, and different functional groups were explored as HBA feature at the differ-
ent positions of the central benzimidazole system. Among synthesized compounds (see Supplementary Table S1 
for some selected derivatives), only analogues 2–4 containing the NHSO2 group as HBA in positions 4–6 of the 
benzimidazole bound the 5-HT6R with moderate affinity (Ki = 200–243 nM, Supplementary Table S1 and Fig. 2). 
Hence, we synthesized new related sulfonamides 5–13 bearing a (dimethylamino)ethyl group as PI and open to 
diverse HYD moieties, based on commonly present systems in 5-HT6R antagonists, such as 5-chloro-2-naphthyl, 
5-chloro-3-methyl-1-benzothiophen-2-yl, or 6-chloroimidazo[2,1-b][1,3]thiazol-5-yl. Additionally, analogues 
14–19 were prepared to study the influence of the halogen atom in this class of ligands (Figs 1D and 2).
Figure 1. Benzimidazole-based compounds targeting the serotonin 5-HT6R receptor. (A) Pharmacophore 
elements for antagonists are a positive ionisable atom (PI, in red), an aromatic ring (AR, in yellow), a hydrogen 
bond acceptor group (HBA, in green), and a hydrophobic site (HYD, in blue). (B) Previously reported 
antagonist with benzimidazole ring as central AR core. (C,D) New series of compounds with the key structural 
elements anchored to the benzimidazole ring.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:41293 | DOI: 10.1038/srep41293
Synthesis. Target compounds 2–19 were synthesized by reaction of the appropriate aminobenzimidazole 
20–22 with the corresponding sulfonyl chloride (Fig. 3). Intermediates 20–22 were obtained according to the syn-
thetic routes detailed in Fig. 4. 4-Nitrobenzimidazole was treated with 2-chloro-N,N-dimethylethylamine and the 
obtained 4- and 7-nitro regioisomers (23 and 24, respectively) were separated by column chromatography. Then, 
pure 23 was reduced to obtain 4-aminobenzimidazole 20. Nucleophilic substitution of 2-fluoro-5-nitroaniline 
with N,N-dimethylethylenediamine followed by Phillips cyclization of 25 with formic acid and nitro reduction of 
26 yielded the corresponding 5-aminobenzimidazole 21. In the case of 6-aminobenzimidazole 22, nucleophilic 
substitution was applied to 3-fluoro-4-nitroaniline, then 27 was cyclized under reductive conditions.
Figure 2. 5-HT6R affinities of new compounds 2–19. aValues are the mean of two to four experiments 
performed in triplicate. b5-HT (Ki = 71 ± 6 nM) and SB-258585 (Ki = 4.5 ± 0.2 nM) were used as reference 
compounds.
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High-affinity ligands 7 and 10 exhibit antagonist character at the human 5-HT6R. Synthesized 
compounds 2–19 were assessed for in vitro affinity at the human 5-HT6R by radioligand competitive binding 
assays, using [3H]LSD in membranes of transfected HEK-293 cells (Fig. 2). In general, ligands anchoring the 
pharmacophore elements (HBA-HYD) at position 6 of the central benzimidazole system exhibited high affinity 
for the 5-HT6R, while positions 4 and 5 were less favorable [7 (Ki = 9 nM) vs 5 (Ki = 64 nM) and 6 (Ki = 112 nM), 
10 (Ki = 25 nM) vs 8 (Ki = 89 nM) and 9 (Ki = 245 nM)]. 6-Benzimidazole derivatives bearing a halogen atom at 
position 5 of the HYD moiety showed the highest affinity values [7 (Ki = 9 nM), 10 (Ki = 25 nM), 16 (Ki = 12 nM), 
and 17 (Ki = 37 nM)], whereas a drop of affinity was observed for analogues 14 and 15 containing a different sub-
stitution pattern in the chloronaphthyl moiety [14 (Ki > 500 nM) and 15 (Ki = 238 nM) vs 7 (Ki = 9 nM)]. Notably, 
removal of the halogen atom in HYD moieties was detrimental for 5-HT6R affinity in 18 and 19 [18 (Ki = 144 nM) 
vs 7 (Ki = 9 nM) and 16 (Ki = 12 nM); 19 (Ki = 195 nM) vs 10 (Ki = 25 nM) and 17 (Ki = 37 nM)].
High-affinity ligands 7 and 10 were assessed for functional activity at the receptor. The effect on adenylate 
cyclase (AC) activity was evaluated in HEK-293 cells expressing the human 5-HT6R. The ligands did not induce 
a substantial increase in cAMP levels, while a complete disappearance of the 5-HT induced response (≥ 95%) 
was attained and a dose-dependent decrease of cAMP concentration was observed for both ligands 7 and 10 
(pIC50 = 7.8 and 7.3, respectively), as well as for SB-258585 used as reference compound (Fig. 5B). These data 
indicate that compounds 7 and 10 act as antagonists at the human 5-HT6R in the AC assay.
Homology models and site-directed mutagenesis define the binding mode to the 5-HT6R. In 
order to rationalize the experimental affinity data we developed computational models of the ligand-receptor 
complexes. To achieve this task, a three-dimensional homology model of the human 5-HT6R was constructed 
from the crystal structure of the closely related 5-HT2B receptor (see Supplementary Figure S3 for sequence 
alignment), which exhibits conformational characteristics of the inactive state11. In our ligand-receptor models 
(Fig. 5A and C), D1063.32 (superscript refers to the Ballesteros–Weinstein nomenclature system) anchors the 
PI (dimethylamino)ethyl group, the central benzimidazole (AR) interacts with C1103.36 and F2856.52, the sul-
fonamide group (HBA) hydrogen bonds N2886.55 and S1935.43, and the terminal HYD system expands into a 
hydrophobic cavity between transmembrane domains (TMs) 3, 4, and 5 (surface in Fig. 5A). As shown in Fig. 5A 
and C, the binding conformation of compounds 7 and 10 is further stabilized by a halogen bond interaction 
between the chlorine substituent in HYD and the A1574.56 backbone carbonyl group (at position i-4 from P4.60, 
see below). Chlorine, as well as bromine and iodine, has a small positively-charged surface (σ -hole) on its hind 
side along the C− Cl bond axis that permits a Lewis acid-base interaction, in which halogen acts as Lewis acid12. 
These halogen bonds are preferentially formed between the halogen atom of the ligand and the carbonyl oxygen 
of the protein backbone, which is the most abundant Lewis base in proteins13. In this regard, serotonin recep-
tors, as well as other GPCRs, contain a break on the main chain hydrogen bond network in TM 4 caused by 
proline residues PP4.60 (in 50% of the human sequences), PxP4.61 (25%) or P4.60 (25%). The break is produced 
Figure 3. Synthesis of target compounds 2–19. Reagents and conditions: (a) pyridine, dichloromethane, rt, 
15 h (2–6, 8–12, 14–19); (b) NaHCO3, acetonitrile, rt, 22 h (7, 13).
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to avoid a steric clash between the pyrrolidine ring of Pro (at position i) and the residue in the preceding turn 
of the helix14, leading to an exposed carbonyl oxygen at position i-4 able to interact with the halogen atom. 
Figure 5D shows P4.60 in the computational model of the 5-HT6R as well as PP and PxP motifs in the crystal 
structures of 5-HT1B and 5-HT2B receptors, respectively10,11. These models explain that in 5-chloro-2-naphthyl 
and 5-chloro-3-methyl-1-benzothiophen-2-yl derivatives the highest affinity is achieved when the HYD moiety is 
anchored at the 6-position of the benzimidazole central core [Ki(7) = 9 nM vs Ki(5) = 64 nM and Ki(6) = 112 nM; 
Ki(10) = 25 nM vs Ki(8) = 89 nM and Ki(9) = 245 nM, respectively] (Fig. 2). The maintenance of nanomolar 
affinity in bromo-HYD analogues [16 (Ki = 12 nM) vs 7 (Ki = 9 nM) and 17 (Ki = 37 nM) vs 10 (Ki = 25 nM)] 
suggests a subtle equilibrium between volume and σ -hole magnitude. Also, the drop of affinity in the case of 
non-halogenated derivatives [18 (Ki = 144 nM) vs 7 (Ki = 9 nM) and 19 (Ki = 195 nM) vs 10 (Ki = 25 nM)] further 
supports the importance of a halogen bond interaction in the HYD moiety to stabilize the binding in this class 
of 5-HT6R ligands. Unbiased 1 μ s molecular dynamics (MD) simulation was used to study the proposed binding 
interactions of the high-affinity compound 7 and its non-halogenated analogue, compound 18 with the 5-HT6R. 
Analysis of the MD trajectories suggested that the predicted complex between compound 7 and the 5-HT6R is 
highly stable, with average ligand root-mean-square deviations (RMSDs) = 1.5 Å relative to the initial docking 
pose. In contrast, compound 18 is less stable (RMSD = 2.2 Å), with larger fluctuations in the HYD group due to 
the absence of the halogen bond stabilizing effect (see Supplementary Figure S4). The evolution of the halogen 
bond distance and the σ -hole angle during the MD simulation are reported in Supplementary Figure S5. The 
average computed values of 3.1 Å and 170°, respectively, are in agreement with bibliographic data12.
Experimental validation of the halogen bond interaction with the backbone carbonyl of A1574.56 is not 
straightforward because its mutation to a different amino acid (except Pro) would not modify the chemical 
composition of the backbone. We, thus, took an indirect approach in which we validated the binding mode of 
compound 7 by mutating all amino acids predicted to form the binding site in the computational model. Ala sub-
stitution of the C1103.36 (pIC50 = 6.8), S1935.43 (5.9), F2856.52 (~4.5), and N2886.55 (6.9) sites decreases the antag-
onist activity of compound 7, relative to wild type (pIC50 = 7.8) (Fig. 5B). This agreement between site-directed 
mutagenesis experiments and computational models points to TMs 3–5 (surface in Fig. 5A) as the cavity to 
accommodate the terminal HYD moiety of the ligand, and supports the backbone carbonyl group of A1574.56, 
within this cavity, as the putative binding partner for the halogen atom. Altogether, these results allowed us to 
expand our previously reported pharmacophore model for 5-HT6R antagonists8. Thus, in addition to the four key 
structural elements —PI, AR, HBA, and HYD—, we propose the importance of a halogen atom attached to HYD 
to form a halogen bond with the free carbonyl group at position 4.56 (Fig. 5E).
New 5-HT6R antagonist 7 exhibits procognitive activity. The high-affinity antagonist 7 was selected 
for the assessment of in vitro pharmacokinetic properties. Metabolic stability using rat and human liver micro-
somes (RLMs and HLMs, respectively) was determined as a measure of first-pass metabolism. Test compound was 
Figure 4. Synthesis of aminobenzimidazoles 20–22. Reagents and conditions: (a) i. Cl(CH2)2N(CH3)2·HCl, 
K2CO3, NaI, DMF, 60 °C, 15 h; ii. column chromatography (SiO2, EtOAc/MeOH 98:2), 23: 33%, 24: 30%; (b) 
H2, 10% Pd(C), MeOH, rt, 15 h, quantitative; (c) H2N(CH2)2N(CH3)2, K2CO3, DMF, 90 °C, 12 h, 60–78%; (d) 
HCOOH, H2O, reflux, 3 h, 92%; (e) 10% Pd(C), HCOOH, MeOH, reflux, 20 h, 69%; (f) 4 M H2SO4, THF, 50 °C, 
1 h, quantitative.
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incubated at a concentration of 1 and 5 μ M with RLM and HLM preparations, respectively. The half-life time (t1/2) 
was used to calculate the intrinsic clearance (CLint). From the data, microsomal metabolism was found to be more 
favourable for HLMs (t1/2 = 77.5 min and CLint = 8.0 mL/min/kg) than for RLMs, where a high rate of degradation 
was found (t1/2 = 20.7 min and CLint = 67.8 mL/min/kg). An in vitro fluorescence-based inhibition assay was con-
ducted with cytochrome P450 2D6 (CYP2D6), one of the most important enzymes involved in drug metabolism, 
using human recombinant microsomal CYP2D6 enzyme, AMMC {3-[2-(N,N-diethyl-N-methylamino)ethyl]-
7-methoxy-4-methylcoumarin} as substrate, and quinidine as control inhibitor. After 30 min of incubation with 
compound 7 at a concentration of 10 μ M, a remaining activity of 78% of the cytochrome was found.
Compound 7 was also tested for interaction with human serum albumin (HSA), and a binding of 70% 
was determined at a concentration of 5 μ M. Additionally, we evaluated the cell permeability of 7 with the 
well-validated parallel artificial membrane permeability assay (PAMPA) technique. The compound showed a 
permeability value (P) of 12 × 10−6 cm/s, intermediate between that of propranolol (P = 25 × 10−6 cm/s) and 
metoprolol (P = 9 × 10−6 cm/s), both highly permeable drugs used as references. To further assess the potential 
of lead compound 7 as a drug candidate, hERG inhibition was determined as an indication of possible lethal side 
effects related with cardiac toxicity. In a hERG whole-cell patch clamp assay 7 showed a low blockade of the K+ 
channel current (IC50 > 10 μ M, n = 3). Moreover, the selectivity of 7 over the serotonin 5-HT2B receptor (16% 
displacement of radioligand at 1 μ M, Supplementary Table S2) exclude a potential cardiac liability associated to 
this receptor15. Altogether, these in vitro studies indicate that the new 5-HT6R antagonist 7 identified in this work 
deserves consideration for further pharmacological characterization.
Subsequently, the in vivo activity of compound 7 was evaluated on the novel object recognition task (NORT) 
in rats, an animal model widely used to assess memory function. As shown in Fig. 6, statistical analysis of the 
results revealed a significant effect for treatment with tested compound 7 and tacrine, which was also assayed for 
comparative purposes. Specifically, 60 min after administration of tacrine (0.5 mg/kg, po) and 7 (1 mg/kg, ip), 
animals spent more time exploring the novel object than the familiar one in the test phase, whereas no significant 
difference was observed in the control group treated with vehicle. The enhanced recognition memory during 
the test phase indicates that compound 7 reversed the time-delay induced memory deficit. These results support 
the procognitive property of the 5-HT6R antagonist newly identified herein, similarly to the behavior observed 
in NORT for other 5-HT6R antagonists such as SB-74245716, clinically tested for the treatment of Alzheimer’s 
disease5. The compound was also assessed for binding affinity toward a set of receptors interacting with cogni-
tive enhancer drugs —serotonin 5-HT1A, 5-HT2A, 5-HT4e, and 5-HT7, histamine H3, muscarinic acetylcholine 
Figure 5. Homology models and site-directed mutagenesis define the binding mode to the 5-HT6R. (A,C) 
Detailed view of the binding modes of compounds 7 (panel A) and 10 (panel C) in the energy-minimized 
computational models of the 5-HT6R. The amino acids of the receptor (labeled according to Ballesteros GPCR 
nomenclature) are shown in green and compounds 7 and 10 in white sticks. The pharmacophore elements PI, 
AR, HBA, and HYD are labeled in panel C according to Fig. 1. Chlorine atoms (purple spheres) of compounds 
7 and 10 halogen bond the carbonyl group at position 4.56 (i-4 relative to Pro 4.60, red dashed lines). (B) 
The antagonist effect (pIC50 values are shown within the parenthesis) of compound 7 is represented as the 
percentage of inhibition of 5-HT-induced stimulation of cAMP taken as 100%, in WT and mutant receptors. 
SB-258585 (pIC50 = 7.6 ± 0.1, dashed line) was assayed in WT as a reference compound. Values are represented 
as mean ± SEM of 3–5 independent experiments each performed in triplicate. (D) Main chain hydrogen 
bond network on the extracellular side of TM 4 in the computational model of the 5-HT6R (left) and crystal 
structures of 5-HT1BR (PDB ID 4IAR, middle) and 5-HT2BR (PDB ID 4IB4, right). Exposed carbonyl oxygens 
(small spheres marked with an asterisk) in TM 4 are free to interact with halogen atoms. (E) Extension of our 
previously reported pharmacophore model for 5-HT6R antagonists, and the predicted interacting amino acids 
in the TMs of the 5-HT6R.
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M1, cannabinoid CB2, α 2 adrenergic, α 7 nicotinic, and NMDA receptors—17,18. In all cases the displacement of 
the corresponding radioligand by compound 7 (at a concentration of 1 μ M) was lower than 23% (see data in 
Supplementary Table S2), indicating no major selectivity concerns over the tested receptors.
Discussion
Among the newly synthesized 5-HT6R ligands described herein (Figs 2, 3 and 4), compounds 7 and 10 have 
been pharmacologically characterized as antagonists at the human receptor in the AC assay (see Results sec-
tion). 5-HT2B-based homology models of ligand-receptor complexes (Fig. 5A and C) predicted interactions of 
the key structural elements —PI ((dimethylamino)ethyl), AR (benzimidazole) and HBA (sulfonamide)— with 
D1063.32, C1103.36, F2856.52, N2886.55, and S1935.43 of the 5-HT6R binding site in TMs 3–6, and an additional sta-
bilization via a halogen bond interaction between the HYD moiety (5-chloro-2-naphthyl or 5-chloro-3-methyl-
1-benzothiophen-2-yl) and the A1574.56 backbone carbonyl group within a hydrophobic cavity in TMs 3–5. These 
models are in agreement with the experimental binding data that revealed the nanomolar affinity exhibited by 
both chloro- and bromo-HYD analogues 7, 10, 16 and 17, and the drop of affinity in non-halogenated deriva-
tives 18 and 19. The decrease of the antagonist activity of compound 7 when the C1103.36, S1935.43, F2856.52, and 
N2886.55 were mutated to Ala (Fig. 5B) validated the predicted binding mode to the 5-HT6R and supported the 
backbone carbonyl group of A1574.56 as the putative binding partner for the halogen atom. Hence, combined 
site-directed mutagenesis and computational studies of this class of antagonists in complex with the 5-HT6R 
expand our pharmacophore model; in addition to the four key structural elements —PI, AR, HBA, and HYD—, 
we propose the importance of a halogen atom attached to the HYD moiety to form a halogen bond with the free 
carbonyl group at position 4.56 (Fig. 5E).
The in vitro ADMET properties —microsomal metabolism, CYP2D6 inhibition, HSA binding, cell permea-
bility, and hERG inhibition— of the 5-HT6R antagonist newly identified herein 7 excluded important pharma-
cokinetic issues and possible lethal side effects related with cardiac toxicity (see Results section). The potential 
of compound 7 as a drug candidate was explored in the NORT assay in rats that revealed a significant reversal 
of the time-delay induced memory deficit when administered at 1 mg/kg (ip) (Fig. 6). The observed effect is in 
agreement with previous studies that have shown that several selective 5-HT6R antagonists are endowed with cog-
nitive enhancing capability19. In addition, the observed selectivity over other receptors interacting with cognitive 
enhancer drugs —serotonin 5-HT1A, 5-HT2A, 5-HT4e, and 5-HT7, histamine H3, muscarinic acetylcholine M1, 
cannabinoid CB2, α 2 adrenergic, α 7 nicotinic, and NMDA— (Supplementary Table S2) suggests that the procog-
nitive activity of 7 is mediated by the 5-HT6R, though an interaction with additional targets can not be discarded.
In conclusion, new benzimidazole-based compounds have been developed as a new class of 5-HT6R antag-
onists. Mutagenesis and homology models have defined the binding mode that includes a halogen bond as an 
important ligand-receptor interaction. The promising in vivo behaviour exhibited by the new selective antagonist 
7 further supports that 5-HT6R antagonists represent a step toward the identification of new cognitive enhancers 
for the treatment of AD and other psychiatric and neurological disorders with associated cognitive dysfunction.
Methods
Chemistry. Unless stated otherwise, starting materials, reagents and solvents were purchased as high-grade 
commercial products from Sigma-Aldrich, ABCR, Acros, Fluorochem, or Scharlab, and were used without fur-
ther purification. Anhydrous tetrahydrofuran (THF) and dichloromethane were dried using a Pure Solv™ Micro 
100 Liter solvent purification system. Analytical thin-layer chromatography (TLC) was run on Merck silica gel 
plates (Kieselgel 60 F-254) with detection by UV light (254 nm), ninhydrin solution, or 10% phosphomolybdic 
acid solution in ethanol. Flash chromatography was performed on a Varian 971-FP flash purification system 
using silica gel cartridges (Varian, particle size 50 μ m). Melting points (mp, uncorrected) were determined on 
a Stuart Scientific electrothermal apparatus. Infrared (IR) spectra were measured on a Bruker Tensor 27 instru-
ment equipped with a Specac ATR accessory of 5200-650 cm−1 transmission range; frequencies (ν ) are expressed 
in cm−1. Nuclear Magnetic Resonance (NMR) spectra were recorded at room temperature on Bruker Avance 
Figure 6. Procognitive activity tested in the novel object recognition task. Effect of compound 7 (1 mg/kg, ip)  
and cognitive enhancer tacrine (0.5 mg/kg, po) on time-induced memory deficit tested in the NORT in rats. 
Data are means ± SEM of exploration times; *P < 0.05 and ***P < 0.001 (paired Student’s t test) indicate 
significant differences of time spent exploring the novel vs familiar objects. N = 8–10 animals/group.
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500 (1H, 500 MHz; 13C, 125 MHz) or Bruker Avance 300-AM (1H, 300 MHz; 13C, 75 MHz) spectrometers at the 
Universidad Complutense de Madrid (UCM) NMR facilities. Chemical shifts (δ ) are expressed in parts per mil-
lion relative to internal tetramethylsilane; coupling constants (J) are in hertz (Hz). The following abbreviations 
are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintet), 
m (multiplet), br (broad), and app (apparent). 2D NMR experiments (HMQC and HMBC) of representative 
compounds were carried out to assign protons and carbons of the new structures and the following abbreviations 
have been used for the peak assignment: benz (benzimidazole), bzthio (benzothiophene), imthiaz (imidazothi-
azole), naph (naphthalene), and Ph (phenyl). Elemental analyses (C, H, N or C, H, N, S) were obtained on a LECO 
CHNS-932 apparatus at the UCM’s analysis services and were within ± 0.4% of the theoretical values, confirming 
a purity of at least 95% for all tested compounds.
HPLC-MS analysis was performed using an Agilent 1200LC-MSD VL instrument. LC separation was 
achieved with an Agilent Eclipse XDB-C18 column (5 μ m, 4.6 mm × 150 mm) together with a guard column 
(5 μ m, 4.6 mm × 12.5 mm). The gradient elution mobile phases consisted of A (95:5 water:methanol) and B (95:5 
methanol:water) with 0.1% formic acid and 0.1% NH4OH as the solvent modifiers. MS analysis was performed 
with an electrospray ionization (ESI) source. The capillary voltage was set to 3.0 kV and the fragmentor voltage 
was set at 70 eV. The drying gas temperature was 350 °C, the drying gas flow rate was 10 L/min and the nebulizer 
pressure was 20 psi. MS measurements were made by selected ion monitoring (SIM).
General procedure for the synthesis of final compounds 2–19. General procedure A. To a solution 
of the corresponding aminobenzimidazole 20–22 in dry dichloromethane (6 mL/mmol), anhydrous pyridine (2 
equiv) was added dropwise at room temperature and under an argon atmosphere. Then, the proper arylsulfonyl 
chloride (1-1.2 equiv) was added and the reaction mixture was stirred for 15 h. The crude was washed with H2O 
and brine, dried (Na2SO4), filtered, and evaporated. The residue was purified by column chromatography using 
the appropriate eluent, to provide pure sulfonamides 2–6, 8–12, 14–19.
General procedure B. To a solution of the 6-aminobenzimidazole 22 in dry acetonitrile (5 mL/mmol), NaHCO3 
(2.8 equiv) was added at room temperature and under an argon atmosphere, and the mixture was stirred for 
15 min. Then, the proper arylsulfonyl chloride (1.05 equiv) was added and the reaction was stirred for 22 h. The 
reaction mixture was filtered and the solvent was evaporated. The residue was purified by column chromatogra-
phy using the appropriate eluent, to provide pure sulfonamides 7, 13.
5-Chloro-N-{1-[2-(dimethylamino)ethyl]-1H-benzimidazol-6-yl}naphthalene-2-sulfonamide 
(7). Obtained from the 6-aminobenzimidazole 22 (101 mg, 0.49 mmol) and 5-chloronaphthalene-2-sulfonyl 
chloride (116 mg, 0.52 mmol) using general procedure B in 34% yield (71 mg). Chromatography: dichlorometh-
ane to dichloromethane/ethanol, 7:3; mp 170 °C (decomposes); IR (ATR) ν 3429, 3064, 1625, 1592, 1501, 1466, 
1322; 1H NMR (300 MHz, DMSO-d6) δ 2.00 (s, 6 H, 2CH3), 2.38 (t, J = 6.1, 2 H, CH2NMe2), 4.16 (t, J = 6.1, 2 H, 
CH2N), 6.92 (dd, J = 8.6, 1.8, 1 H, CHbenz), 7.22 (d, J = 1.8, 1 H, CHbenz), 7.45 (d, J = 8.6, 1 H, CHbenz), 7.60 (t, 
J = 8.0, 1 H, CHnaph), 7.85 (d, J = 6.9, 1 H, CHnaph), 7.94 (dd, J = 9.0, 1.8, 1 H, CHnaph), 8.08–8.12 (m, 2 H, CHbenz, 
CHnaph), 8.31 (d, J = 9.0, 1 H, CHnaph), 8.47 (d, J = 1.8, 1 H, CHnaph), 10.37 (br s, 1 H, NH); 13C NMR (75 MHz, 
DMSO-d6) δ 42.1 (CH2), 44.9 (2CH3), 57.7 (CH2), 103.5, 116.8, 119.7, 123.9, 125.4, 128.0, 128.5, 128.9, 129.1 
(9CH), 130.6, 131.1, 132.0, 132.9, 133.7, 137.6, 140.8 (7 C), 144.8 (CH); MS (ESI) 429.2 [M(35Cl) + H]+, 431.2 
[M(37Cl) + H]+. Anal. (C21H21ClN4O2S) C, H, N, S.
5-HT6R radioligand binding assay. Competitive inhibition assays were carried out following previously 
reported procedure20.
5-HT6R AC assay. Experimental details for cell cultures, transfection, expression vectors, mutagenesis, and 
cAMP measurements are fully described in the Supporting Information. Briefly, 24 h after transfection, cells 
were incubated in Dulbecco’s modified Eagle’s serum-free medium for 4 h. Prior to the experiments, cell culture 
medium was replaced and plates were equilibrated for 1 h with 100 μ L of assay medium at room temperature in 
the dark. The assay medium consisted in Hank’s Balanced Salt Solution (HBSS) with 24 mM HEPES, 3.3 mM 
Na2CO3, 1.3 mM CaCl2, 1 mM MgSO4, 0.1% (w/v) bovine serum albumin and 0.45 mg/mL D-Luciferin (all 
reagents were purchased from Sigma-Aldrich, UK, with the exception of D-Luciferin, Nanolight® Technology, 
USA). Bioluminescence was quantified using a CLARIOstar® Multimode Plate Reader (BMG Labtech, Germany) 
with 1 s integration time/well. Prior to treatment of cells, 5 measurements were made, at 2-min intervals, to 
determine the basal luminescence levels. To account for differences in expression/cell density, the average of these 
5 pre-readings was used to normalize each well’s response. To determine the potency of 5-HT for 5-HT6 wild 
type and mutant receptors, different concentrations of 5-HT or tested compound were added and 20 measure-
ments were taken in kinetic mode every 2 min. For real-time competition experiments, tested compounds were 
pre-incubated for 20 min prior to 5-HT stimulation (10 × 5-HT EC50 for each receptor form to ensure > 90% 
receptor occupancy, see Supplementary Figure S2). The area under the curve was used to fit the dose-response 
curves by nonlinear regression using a three parameters logistic equation. Data were analyzed using GraphPad 
Prism 6.0 h (GraphPad Software, La Jolla, CA).
In vitro pharmacokinetics. RLM and HLM stability, HSA binding, and fluorescence-based CYP2D6 inhi-
bition assays were performed according to previously reported procedures21. Inhibition of hERG K+ channel 
current was determined in an automated patch clamp assay using whole CHO-K1 cells at Eurofins Panlab (USA), 
according to previously published method22.
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The assessment of the membrane permeability of ligand 7 and reference compounds propranolol and metopr-
olol was performed in a commercially available 96-well Corning Gentest pre-coated PAMPA plate system (Cultek 
S.L.U., Spain). Prior to use, the pre-coated PAMPA plate system was warmed to room temperature for 30 min 
and 300 μ L of 200 μ M solution of tested compound in 2% DMSO in phosphate buffered saline (PBS, pH 7.4) were 
added into wells in the receiver (donor) plate. Then 200 μ L of PBS were added into wells in the filter (acceptor) 
plate. The filter plate was placed on the receiver plate by slowly lowering the pre-coated PAMPA plate until it sits 
on the receiver plate. The assembly was incubated at 25 °C for 5 h, and then buffer samples were collected care-
fully from each plate. The final concentrations of compound in both donor and acceptor wells were analyzed by 
HPLC-MS and quantification was estimated by using the peak area integration normalized with an internal stand-
ard. Permeability value of the compounds was calculated using the following formula: P (cm/s) = {− ln[1 − CA(t)/
Ceq]}/[A*(1/VD + 1/VA)*t], where A = filter area (0.3 cm2), VD = donor well volume (0.3 mL), VA = acceptor 
well volume (0.2 mL), t = incubation time (s), CA(t) = compound concentration (μ M) in acceptor well at time 
t, CD(t) = compound concentration (μ M) in donor well at time t, and Ceq = [CD(t)*VD + CA(t)*VA]/(VD + VA). 
Assays were performed in duplicate and the compounds were tested in two different plates on different days.
NORT assay. The novel object recognition task was conducted at Suven Life Sciences (Hyderabad, India) 
according to previously reported method19. All animal care and experiments were carried out in compliance with 
Institutional Animal Ethics Committee (IAEC) requirements and in-house animal care and usage policy. Every 
effort was made to reduce the number of animals used and to minimize potential suffering. The experiment was 
carried out using male Wistar rats (220–280 g) over a period of three days. Briefly, on day 1 (habituation session) 
the rats were habituated for 20 min to the experimental conditions and then returned to their respective home 
cages. On day 2 (acquisition session) the rats were allowed to explore two similar objects for 3 min. After this 
familiarization phase, animals were returned to their home cages. On day 3 (recognition session), 24 h after the 
familiarization phase, one object presented during the acquisition session was replaced by a new object. The rats 
were allowed to explore the familiar and the novel objects for 3 min. The times spent by each animal investigating 
each of the objects were recorded separately in both acquisition and recognition sessions. Exploration times of 
≥ 15 s during the acquisition phase and ≥ 10 s during the recognition phase were considered for statistical analysis. 
Compound 7 (1 mg/kg, ip) or tacrine (0.5 mg/kg, po) or vehicle (2 mL/kg, ip) were administered 60 min before 
each session of the test.
Computational model of ligand-receptor complexes. MODELLER v9.1223 was used to build a homol-
ogy model of human 5-HT6R (Uniprot code P50406) (one hundred molecular models were generated) using the 
three-dimensional crystal structure of the 5-HT2BR (PDB code 4IB4) as template10. Sequences were aligned using 
the highly conserved residues shared within the GPCR family (see Supplementary Figure S3)24. Loops regions 
were optimized through a MD Simulated Annealing protocol. For this purpose, backbone residues of TMs and 
Helix 8 were constrained and the conformation of loops were optimized in 20 Simulated Annealing cycles of heat-
ing up to 700 K and slowly cooling down to 300 K in successive 10 K, 100 ps steps followed by an energy minimiza-
tion. Compounds 7, 10 and 18 were docked into the receptor model using the AutoDock Vina tool25. All docking 
solutions were visually inspected and the poses in which the protonated amine forms an ionic interaction with 
D1063.32 and the NHSO2 group hydrogen bonds N2886.55 were energy minimized. The binding modes of com-
pounds 7 and 18 to the 5-HT6R were further studied in explicit membrane MD simulations with the GROMACS 
v4.5.3 simulation package26 (see Supplementary Figures S4–S6). Molecular systems were subjected to 50 ns of 
equilibration, with positional restraints on the backbone atoms of the receptor. These restraints were released, and 
1 μ s MD trajectory was produced at constant pressure and temperature, using the particle mesh Ewald method 
to evaluate electrostatic interactions. The AMBER99SB-ILDN force field was used for the protein, Berger param-
eters for the lipids, and the general Amber force field (GAFF) and HF/6–31 G*-derived RESP atomic charges for 
the ligand. This procedure has been previously validated27. The chlorine atom of compound 7 was parameterized 
according to the positive-extra-point approach proposed by Ibrahim28. As a result, two point charges separated 
by 1.9 Å (a negative charge [− 0.0725e] centered on the halogen atom to reproduce the electronegative crown, 
and a positive charge [+ 0.04e] centered on a dummy atom on the hind side of the C− Cl bond axis in order to 
reproduce the positively-charged σ -hole) were used to account for the potential effect of halogen bonding in the 
standard force field29.
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